Menu Menu

Guidelines update, version 33.1

05 February, 2021

Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include:

  • Additional remark added to the recommendation for Sarilumab:

The Taskforce notes the preprint of the adaptive, multicentre trial by Lescure et al., posted to medRxiv on 3 February, which randomised 420 patients with severe or critical COVID-19 to sarilumab (200 mg or 400 mg) or placebo. This study is currently under review and an updated recommendation will be included in a future version of the guideline.